Nascent Pharma Holdings, Inc.
NASC
$0.02
$0.00-8.33%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 15.30K | 272.30K | 369.10K | 376.90K | 419.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.30K | 272.30K | 369.10K | 376.90K | 419.00K |
| Cost of Revenue | 415.80K | 665.50K | 1.19M | -897.60K | 1.24M |
| Gross Profit | -400.50K | -393.20K | -824.10K | 1.27M | -816.70K |
| SG&A Expenses | 2.43M | 1.17M | 1.59M | -1.17M | 2.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | 3.10M | -- |
| Total Operating Expenses | 2.85M | 1.84M | 2.79M | 1.03M | 4.00M |
| Operating Income | -2.83M | -1.57M | -2.42M | -651.70K | -3.58M |
| Income Before Tax | -3.26M | -2.03M | -6.16M | -1.81M | -4.17M |
| Income Tax Expenses | -- | -- | -- | 0.00 | -- |
| Earnings from Continuing Operations | -3.26M | -2.03M | -6.16M | -1.81M | -4.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.26M | -2.03M | -6.16M | -1.81M | -4.17M |
| EBIT | -2.83M | -1.57M | -2.42M | -651.70K | -3.58M |
| EBITDA | -2.83M | -1.54M | -2.10M | -301.70K | -3.23M |
| EPS Basic | -0.05 | -0.04 | -0.17 | -0.06 | -0.36 |
| Normalized Basic EPS | -0.03 | -0.02 | -0.05 | -0.04 | -0.22 |
| EPS Diluted | -0.05 | -0.04 | -0.17 | -0.06 | -0.36 |
| Normalized Diluted EPS | -0.03 | -0.02 | -0.05 | -0.04 | -0.22 |
| Average Basic Shares Outstanding | 65.44M | 54.63M | 37.34M | 28.29M | 11.59M |
| Average Diluted Shares Outstanding | 65.44M | 54.63M | 37.34M | 28.29M | 11.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |